Press Release
Ziopharm Oncology Presents Preclinical Data Supporting TCR-T Library Approach at the Society for Immunotherapy of Cancer 2021 Annual Meeting
“We are pleased to share preclinical data demonstrating the versatility of our Sleeping Beauty technology to develop neoantigen-specific TCR-T cells with the potential to address a wide range of solid tumor indications,” commented
Details of Ziopharm’s SITC 2021 presentation are as follows:
Title: Neoantigen-specific TCR-T cells targeting shared hotspot mutations for adoptive cell therapy in common epithelial cancers
Presenter:
Date/Time:
Location:
Abstract Number: 226
In the study presented at SITC, Ziopharm’s non-viral gene transfer technology, Sleeping Beauty, was used to develop TCR-T cells targeting EGFR, KRAS and p53 neoantigens, which are present in cancer cells but not in normal tissue, and are presented by a variety of human leukocyte antigen (HLA) molecules on the cancer cell surface. Ziopharm’s Sleeping Beauty technology exhibited greater than 60% expression of the introduced neoantigen-specific TCRs in the generated TCR-T cells. The study demonstrated that the neoantigen-specific TCR-T cells successfully targeted tumor cells expressing EGFR, KRAS and p53 neoantigens in conjunction with the matching HLA restriction. Importantly, these TCR’s did not recognize cells lacking the matching mutations and HLA restrictions.
About
Ziopharm is a clinical-stage cell therapy company, focused on developing T-cell receptor (TCR) therapies for a wide range of solid tumor indications. The Company’s non-viral Sleeping Beauty gene transfer platform has enabled the development of a unique
Forward-Looking Statements Disclaimer
This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts, and in some cases can be identified by terms such as “may,” “will,” “could,” “expects,” “plans,” “anticipates,” and “believes.” These statements include, but are not limited to, statements regarding the Company's business and strategic plans, the timing of activities relating to the Company’s GMP facility, the execution of potential future partnerships or transactions, and the timing of the Company's research and development programs, including the anticipated dates for enrolling patients in the Company’s TCR-T clinical trial. Although Ziopharm’s management team believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Ziopharm, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include, among other things, changes in the Company’s operating plans that may impact its cash expenditures, the uncertainties inherent in research and development, future clinical data and analysis, including whether any of Ziopharm’s product candidates will advance further in the preclinical research or clinical trial process, including receiving clearance from the
Investor Relations Contact:
Stern Investor Relations
Alex.lobo@sternir.com
Source: ZIOPHARM Oncology Inc